In the ever-evolving field of Alzheimer’s disease (AD) research, the development of disease-modifying therapies has sparked both excitement and debate. While these therapies represent a promising shift in the treatment landscape, questions remain about their clinical benefits, risks and economic impact. The controversies surrounding these therapies have led to apprehension among clinicians about prescribing them to their patients.
↧